

Rhythm Expands ColoSTAT® Clinical Trial To Tenth Site

- **Sunshine Coast University Hospital joins Rhythm's ColoSTAT® clinical trial;**
- **Dr Andrew Sloss appointed as Principal Investigator; and**
- **First patients recruited.**

11 February 2021, Melbourne: Rhythm Biosciences Limited (ASX: RHY) is pleased to confirm that Sunshine Coast University Hospital, Queensland, joins as the tenth site as part of Rhythm's ColoSTAT® Clinical Trial (Study 7). ColoSTAT® is aimed to be a globally marketed, low-cost, simple blood test for the early detection of colorectal cancer for mass-market screening.

Sunshine Coast University Hospital is located 9km north of Caloundra and is the first trial site in Queensland. The hospital is a major provider of public health services and research in the Sunshine Coast, Gympie and Noosa local government areas, and includes a dedicated centre for clinical research which is resourced with gastroenterology nurses as study co-ordinators to facilitate recruitment. The Principal Investigator, Dr Andrew Sloss, is a gastroenterologist and senior lecturer at the University of Queensland.

Dr Andrew Sloss commented:

"We currently treat hundreds of bowel cancer patients each year, which highlights the significant public need for effective screening and early intervention. ColoSTAT® presents us with this opportunity to do both, ultimately easing the burden on the health system, and more importantly, to save lives."

Rhythm CEO, Mr Glenn Gilbert, added:

"A milestone of ten sites now participating in our ColoSTAT® clinical trial ensures we remain on track to positively impact people's lives, by delivering a simple way to detect colorectal cancer early. Whilst an Australian invention, beginning at the CSIRO, Rhythm's aim is to address the global market through mass screening programs."

Rhythm Biosciences continues to conduct feasibility on further sites to join the ColoSTAT® trial, ensuring continued progress in Study 7 patient recruitment.

With authority of the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.